Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The old COPD playbook — steroids, antibiotics, and hope — is getting a major rethink. Experts at ERS 2026 argued that respiratory viruses trigger ~50% of COPD flares, yet treatment often starts too late to matter. The new vision: early home testing, patient-initiated therapy, and targeting both the viral spark and the inflamed airway "terrain" to hit GOLD's ambitious zero-exacerbation goal.
The standard response to a viral COPD flare — oral corticosteroids, broad-spectrum antibiotics, and watchful waiting — is increasingly seen as too little, too late. At the ERS 2026 International Congress in Barcelona, leading respiratory experts made the case for a fundamental shift: from reactive, syndromic rescue to precision strategies that target both the viral trigger and the underlying inflammatory environment driving lung damage.
A key obstacle is timing. Viral replication peaks within 1–2 days of symptom onset, but most patients don't seek care until day 5 or later — well past the antiviral window. Compounding this, COPD airways mount a delayed immune response (72–96 hours vs. 48 hours in healthy tissue), allowing unchecked viral replication before inflammation takes over. Early-life RSV infections also set the stage, permanently lowering lung function trajectories and predisposing individuals to COPD decades later.
Key Takeaways:
Why it matters: COPD exacerbations aren't just bad days — even a single moderate flare permanently alters a patient's survival curve. Shifting to precision, upstream interventions could transform outcomes for millions of patients worldwide.
